Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2011, Article ID 859802, 4 pages
http://dx.doi.org/10.1155/2011/859802
Case Report

Anti-MuSK-Positive Myasthenia Gravis in a Patient with Parkinsonism and Cognitive Impairment

1Department of Neurological Sciences, Dino Ferrari Centre, University of Milan, 20122 Milan, Italy
2IRCCS Foundation Ospedale Maggiore Policlinico Mangiagalli and Regina Elena, Via F. Sforza 35, 20122 Milan, Italy

Received 22 December 2010; Revised 6 April 2011; Accepted 2 May 2011

Academic Editor: Richard A. Wennberg

Copyright © 2011 S. Lanfranconi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Vincent, J. Bowen, J. Newsom-Davis, and J. McConville, “Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets,” Lancet Neurology, vol. 2, no. 2, pp. 99–106, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. V. C. Juel and J. M. Massey, “Myasthenia gravis,” Orphanet Journal of Rare Diseases, vol. 2, no. 1, Article ID 44, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. G. I. Wolfe and S. J. Oh, “Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis,” Annals of the New York Academy of Sciences, vol. 1132, pp. 71–75, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. F. Scuderi, M. Marino, L. Colonna et al., “Anti-P110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement,” Laboratory Investigation, vol. 82, no. 9, pp. 1139–1146, 2002. View at Google Scholar · View at Scopus
  5. A. Evoli, P. A. Tonali, L. Padua et al., “Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis,” Brain, vol. 126, no. 10, pp. 2304–2311, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. E. Farrugia, M. D. Robson, L. Clover et al., “MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis,” Brain, vol. 129, no. 6, pp. 1481–1492, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. M. Valenzuela, T. N. Stitt, P. S. DiStefano et al., “Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury,” Neuron, vol. 15, no. 3, pp. 573–584, 1995. View at Google Scholar · View at Scopus
  8. H. Shiraishi, M. Motomura, T. Yoshimura et al., “Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis,” Annals of Neurology, vol. 57, no. 2, pp. 289–293, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. T. M. DeChiara, D. C. Bowen, D. M. Valenzuela et al., “The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo,” Cell, vol. 85, no. 4, pp. 501–512, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Vincent and M. I. Leite, “Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis,” Current Opinion in Neurology, vol. 18, no. 5, pp. 519–525, 2005. View at Google Scholar · View at Scopus
  11. T. Eckert, C. Tang, Y. Ma et al., “Abnormal metabolic networks in atypical parkinsonism,” Movement Disorders, vol. 23, no. 5, pp. 727–733, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. I. Litvan, Y. Agid, D. Calne et al., “Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop,” Neurology, vol. 47, no. 1, pp. 1–9, 1996. View at Google Scholar · View at Scopus
  13. A. Pisani, G. Bernardi, J. Ding, and D. J. Surmeier, “Re-emergence of striatal cholinergic interneurons in movement disorders,” Trends in Neurosciences, vol. 30, no. 10, pp. 545–553, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. N. M. Warren, M. A. Piggott, E. K. Perry, and D. J. Burn, “Cholinergic systems in progressive supranuclear palsy,” Brain, vol. 128, no. 2, pp. 239–249, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. P. A. Pahapill and A. M. Lozano, “The pedunculopontine nucleus and Parkinson's disease,” Brain, vol. 123, no. 9, pp. 1767–1783, 2000. View at Google Scholar · View at Scopus
  16. E. K. Perry, C. J. Smith, J. A. Court, and R. H. Perry, “Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types,” Journal of Neural Transmission Parkinson's Disease and Dementia Section, vol. 2, no. 3, pp. 149–158, 1990. View at Google Scholar · View at Scopus
  17. J. O. Rinne, T. Myllykylä, P. Lönnberg, and P. Marjamaki, “A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease,” Brain Research, vol. 547, no. 1, pp. 167–170, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. S. L. Pimlott, M. Piggott, J. Owens et al., “Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380,” Neuropsychopharmacology, vol. 29, no. 1, pp. 108–116, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. A. Garcia-Osta, P. Tsokas, G. Pollonini, E. M. Landau, R. Blitzer, and C. M. Alberini, “MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation,” Journal of Neuroscience, vol. 26, no. 30, pp. 7919–7932, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. V. D. Bohbot, L. Nadel, R. Jech, E. Ruzicka, and J. Bures, “Spatial and nonspatial memory involvement in myasthenia gravis,” Journal of Neurology, vol. 244, no. 8, pp. 529–532, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. W. Hoch, J. Mcconville, S. Helms, J. Newsom-Davis, A. Melms, and A. Vincent, “Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies,” Nature Medicine, vol. 7, no. 3, pp. 365–368, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus